The Effect of Upfront Intensive Therapy on Primary Resistance in Metastatic Castration-sensitive Prostate Cancer: A Multicenter Retrospective Study Article Swipe
Toshikazu Tanaka
,
Shingo Hatakeyama
,
Daisuke Noro
,
Hirotake Kodama
,
Sakae Konishi
,
Kazutaka Okita
,
Shogo Hosogoe
,
Kai Ozaki
,
Takuma Narita
,
Noriko Tokui
,
Teppei Okamoto
,
Hayato Yamamoto
,
Atsushi Imai
,
Takahiro Yoneyama
,
Yasuhiro Hashimoto
,
Chikara Οhyama
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-711200/v1
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-711200/v1
We investigated the effect of upfront intensive therapy on primary resistance in patients with metastatic castration-sensitive prostate cancer (mCSPC) in real-world practice. We retrospectively evaluated the medical records of 348 patients with newly diagnosed mCSPC who had a high tumor-burden between January 2008 and May 2021. We compared the oncological outcomes between patients who received conventional androgen deprivation therapy ± bicalutamide (ADT group) and those treated with upfront intensive therapies (upfront group). The primary purpose was comparing the rate of primary resistance between the ADT and upfront groups. The primary resistance was defined as a castration-resistant prostate cancer (CRPC) progression < 6 or < 12 months. The secondary purposes were comparing the CRPC-free survival and overall survival (OS) between the ADT and upfront groups, and assessing safety in the upfront group. We identified 206 and 142 patients for the ADT and upfront groups, respectively. We found the rate of CRPC progression < 6 and < 12 months was significantly lower in the upfront group (9.2% and 18%, respectively) than that in the ADT group (21% and 51%, respectively). The upfront therapy was significantly associated with favorable CRPC-free survival and OS than that in the ADT group in propensity-score adjusted models. A higher rate of any grade adverse events was observed in the upfront docetaxel (94%) than that of the upfront abiraterone (34%) or apalutamide/enzalutamide (39%). In conclusion, the upfront intensive therapy significantly improved the rate of primary resistance and oncological outcomes in patients with mCSPC in real-world practice.
Related Topics
Concepts
Enzalutamide
Medicine
Prostate cancer
Oncology
Internal medicine
Androgen deprivation therapy
Propensity score matching
Progression-free survival
Adverse effect
Abiraterone acetate
Docetaxel
Overall survival
Cancer
Androgen receptor
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.21203/rs.3.rs-711200/v1
- https://www.researchsquare.com/article/rs-711200/latest.pdf
- OA Status
- green
- References
- 28
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3190146326
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3190146326Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21203/rs.3.rs-711200/v1Digital Object Identifier
- Title
-
The Effect of Upfront Intensive Therapy on Primary Resistance in Metastatic Castration-sensitive Prostate Cancer: A Multicenter Retrospective StudyWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-08-06Full publication date if available
- Authors
-
Toshikazu Tanaka, Shingo Hatakeyama, Daisuke Noro, Hirotake Kodama, Sakae Konishi, Kazutaka Okita, Shogo Hosogoe, Kai Ozaki, Takuma Narita, Noriko Tokui, Teppei Okamoto, Hayato Yamamoto, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara ΟhyamaList of authors in order
- Landing page
-
https://doi.org/10.21203/rs.3.rs-711200/v1Publisher landing page
- PDF URL
-
https://www.researchsquare.com/article/rs-711200/latest.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.researchsquare.com/article/rs-711200/latest.pdfDirect OA link when available
- Concepts
-
Enzalutamide, Medicine, Prostate cancer, Oncology, Internal medicine, Androgen deprivation therapy, Propensity score matching, Progression-free survival, Adverse effect, Abiraterone acetate, Docetaxel, Overall survival, Cancer, Androgen receptorTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
28Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3190146326 |
|---|---|
| doi | https://doi.org/10.21203/rs.3.rs-711200/v1 |
| ids.doi | https://doi.org/10.21203/rs.3.rs-711200/v1 |
| ids.mag | 3190146326 |
| ids.openalex | https://openalex.org/W3190146326 |
| fwci | 0.0 |
| type | preprint |
| title | The Effect of Upfront Intensive Therapy on Primary Resistance in Metastatic Castration-sensitive Prostate Cancer: A Multicenter Retrospective Study |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10543 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Prostate Cancer Treatment and Research |
| topics[1].id | https://openalex.org/T11395 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9968000054359436 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2741 |
| topics[1].subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| topics[1].display_name | Radiopharmaceutical Chemistry and Applications |
| topics[2].id | https://openalex.org/T11914 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9865999817848206 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | PARP inhibition in cancer therapy |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2776551883 |
| concepts[0].level | 5 |
| concepts[0].score | 0.8471882343292236 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1996756 |
| concepts[0].display_name | Enzalutamide |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.8400673866271973 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2780192828 |
| concepts[2].level | 3 |
| concepts[2].score | 0.8015978336334229 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q181257 |
| concepts[2].display_name | Prostate cancer |
| concepts[3].id | https://openalex.org/C143998085 |
| concepts[3].level | 1 |
| concepts[3].score | 0.654572606086731 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[3].display_name | Oncology |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6292781829833984 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C2777899217 |
| concepts[5].level | 4 |
| concepts[5].score | 0.605312705039978 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q4759439 |
| concepts[5].display_name | Androgen deprivation therapy |
| concepts[6].id | https://openalex.org/C17923572 |
| concepts[6].level | 2 |
| concepts[6].score | 0.45021751523017883 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7250160 |
| concepts[6].display_name | Propensity score matching |
| concepts[7].id | https://openalex.org/C2780739268 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4436712861061096 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2112244 |
| concepts[7].display_name | Progression-free survival |
| concepts[8].id | https://openalex.org/C197934379 |
| concepts[8].level | 2 |
| concepts[8].score | 0.435520738363266 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[8].display_name | Adverse effect |
| concepts[9].id | https://openalex.org/C2775832370 |
| concepts[9].level | 5 |
| concepts[9].score | 0.42098402976989746 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q27888393 |
| concepts[9].display_name | Abiraterone acetate |
| concepts[10].id | https://openalex.org/C2781190966 |
| concepts[10].level | 3 |
| concepts[10].score | 0.41349565982818604 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q420436 |
| concepts[10].display_name | Docetaxel |
| concepts[11].id | https://openalex.org/C3019894029 |
| concepts[11].level | 2 |
| concepts[11].score | 0.3515530228614807 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q332823 |
| concepts[11].display_name | Overall survival |
| concepts[12].id | https://openalex.org/C121608353 |
| concepts[12].level | 2 |
| concepts[12].score | 0.2850865423679352 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[12].display_name | Cancer |
| concepts[13].id | https://openalex.org/C61367390 |
| concepts[13].level | 4 |
| concepts[13].score | 0.11757928133010864 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q416601 |
| concepts[13].display_name | Androgen receptor |
| keywords[0].id | https://openalex.org/keywords/enzalutamide |
| keywords[0].score | 0.8471882343292236 |
| keywords[0].display_name | Enzalutamide |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.8400673866271973 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/prostate-cancer |
| keywords[2].score | 0.8015978336334229 |
| keywords[2].display_name | Prostate cancer |
| keywords[3].id | https://openalex.org/keywords/oncology |
| keywords[3].score | 0.654572606086731 |
| keywords[3].display_name | Oncology |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.6292781829833984 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/androgen-deprivation-therapy |
| keywords[5].score | 0.605312705039978 |
| keywords[5].display_name | Androgen deprivation therapy |
| keywords[6].id | https://openalex.org/keywords/propensity-score-matching |
| keywords[6].score | 0.45021751523017883 |
| keywords[6].display_name | Propensity score matching |
| keywords[7].id | https://openalex.org/keywords/progression-free-survival |
| keywords[7].score | 0.4436712861061096 |
| keywords[7].display_name | Progression-free survival |
| keywords[8].id | https://openalex.org/keywords/adverse-effect |
| keywords[8].score | 0.435520738363266 |
| keywords[8].display_name | Adverse effect |
| keywords[9].id | https://openalex.org/keywords/abiraterone-acetate |
| keywords[9].score | 0.42098402976989746 |
| keywords[9].display_name | Abiraterone acetate |
| keywords[10].id | https://openalex.org/keywords/docetaxel |
| keywords[10].score | 0.41349565982818604 |
| keywords[10].display_name | Docetaxel |
| keywords[11].id | https://openalex.org/keywords/overall-survival |
| keywords[11].score | 0.3515530228614807 |
| keywords[11].display_name | Overall survival |
| keywords[12].id | https://openalex.org/keywords/cancer |
| keywords[12].score | 0.2850865423679352 |
| keywords[12].display_name | Cancer |
| keywords[13].id | https://openalex.org/keywords/androgen-receptor |
| keywords[13].score | 0.11757928133010864 |
| keywords[13].display_name | Androgen receptor |
| language | en |
| locations[0].id | doi:10.21203/rs.3.rs-711200/v1 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306402450 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Research Square (Research Square) |
| locations[0].source.host_organization | https://openalex.org/I4210096694 |
| locations[0].source.host_organization_name | Research Square (United States) |
| locations[0].source.host_organization_lineage | https://openalex.org/I4210096694 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.researchsquare.com/article/rs-711200/latest.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.21203/rs.3.rs-711200/v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5076075777 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-0711-7880 |
| authorships[0].author.display_name | Toshikazu Tanaka |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210090794 |
| authorships[0].affiliations[0].raw_affiliation_string | Aomori Prefectural Central Hospital |
| authorships[0].institutions[0].id | https://openalex.org/I4210090794 |
| authorships[0].institutions[0].ror | https://ror.org/00bq8v746 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210090794 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Aomori Prefectural Central Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Toshikazu Tanaka |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Aomori Prefectural Central Hospital |
| authorships[1].author.id | https://openalex.org/A5109393567 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Shingo Hatakeyama |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[1].affiliations[0].raw_affiliation_string | Hirosaki University Graduate School of Medicine |
| authorships[1].institutions[0].id | https://openalex.org/I146516829 |
| authorships[1].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Hirosaki University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Shingo Hatakeyama |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Hirosaki University Graduate School of Medicine |
| authorships[2].author.id | https://openalex.org/A5030262604 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-7104-0945 |
| authorships[2].author.display_name | Daisuke Noro |
| authorships[2].affiliations[0].raw_affiliation_string | Mutsu General Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Daisuke Noro |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Mutsu General Hospital |
| authorships[3].author.id | https://openalex.org/A5008863548 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5071-5149 |
| authorships[3].author.display_name | Hirotake Kodama |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[3].affiliations[0].raw_affiliation_string | Hirosaki University Graduate School of Medicine |
| authorships[3].institutions[0].id | https://openalex.org/I146516829 |
| authorships[3].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Hirosaki University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Hirotake Kodama |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Hirosaki University Graduate School of Medicine |
| authorships[4].author.id | https://openalex.org/A5029041044 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Sakae Konishi |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[4].affiliations[0].raw_affiliation_string | Hirosaki University Graduate School of Medicine |
| authorships[4].institutions[0].id | https://openalex.org/I146516829 |
| authorships[4].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Hirosaki University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Sakae Konishi |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Hirosaki University Graduate School of Medicine |
| authorships[5].author.id | https://openalex.org/A5112753941 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Kazutaka Okita |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[5].affiliations[0].raw_affiliation_string | Hirosaki University Graduate School of Medicine |
| authorships[5].institutions[0].id | https://openalex.org/I146516829 |
| authorships[5].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Hirosaki University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Kazutaka Okita |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Hirosaki University Graduate School of Medicine |
| authorships[6].author.id | https://openalex.org/A5089675766 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Shogo Hosogoe |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210092407 |
| authorships[6].affiliations[0].raw_affiliation_string | Aomori City Hospital |
| authorships[6].institutions[0].id | https://openalex.org/I4210092407 |
| authorships[6].institutions[0].ror | https://ror.org/00fc19b96 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210092407 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Aomori Rosai Hospital |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Shogo Hosogoe |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Aomori City Hospital |
| authorships[7].author.id | https://openalex.org/A5048511847 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Kai Ozaki |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[7].affiliations[0].raw_affiliation_string | Hirosaki University Graduate School of Medicine |
| authorships[7].institutions[0].id | https://openalex.org/I146516829 |
| authorships[7].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | Hirosaki University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Kai Ozaki |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Hirosaki University Graduate School of Medicine |
| authorships[8].author.id | https://openalex.org/A5044499778 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-2572-3590 |
| authorships[8].author.display_name | Takuma Narita |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210149837 |
| authorships[8].affiliations[0].raw_affiliation_string | Hirosaki National Hospital, National Hospital Organization |
| authorships[8].institutions[0].id | https://openalex.org/I4210149837 |
| authorships[8].institutions[0].ror | https://ror.org/03qrrp624 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210137409, https://openalex.org/I4210149837 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Hirosaki National Hospital |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Takuma Narita |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Hirosaki National Hospital, National Hospital Organization |
| authorships[9].author.id | https://openalex.org/A5112691410 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Noriko Tokui |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210135139 |
| authorships[9].affiliations[0].raw_affiliation_string | Odate Municipal Hospital |
| authorships[9].institutions[0].id | https://openalex.org/I4210135139 |
| authorships[9].institutions[0].ror | https://ror.org/03k7veg12 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210135139 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | Odawara Municipal Hospital |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Noriko Tokui |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Odate Municipal Hospital |
| authorships[10].author.id | https://openalex.org/A5026803124 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-3750-3811 |
| authorships[10].author.display_name | Teppei Okamoto |
| authorships[10].countries | JP |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[10].affiliations[0].raw_affiliation_string | Hirosaki University Graduate School of Medicine |
| authorships[10].institutions[0].id | https://openalex.org/I146516829 |
| authorships[10].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[10].institutions[0].country_code | JP |
| authorships[10].institutions[0].display_name | Hirosaki University |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Teppei Okamoto |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Hirosaki University Graduate School of Medicine |
| authorships[11].author.id | https://openalex.org/A5013782799 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-4557-0619 |
| authorships[11].author.display_name | Hayato Yamamoto |
| authorships[11].countries | JP |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[11].affiliations[0].raw_affiliation_string | Hirosaki University Graduate School of Medicine |
| authorships[11].institutions[0].id | https://openalex.org/I146516829 |
| authorships[11].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[11].institutions[0].country_code | JP |
| authorships[11].institutions[0].display_name | Hirosaki University |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Hayato Yamamoto |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Hirosaki University Graduate School of Medicine |
| authorships[12].author.id | https://openalex.org/A5101461132 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-7691-4982 |
| authorships[12].author.display_name | Atsushi Imai |
| authorships[12].countries | GB |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I2801030792 |
| authorships[12].affiliations[0].raw_affiliation_string | Oyokyo Kidney Research Institute |
| authorships[12].institutions[0].id | https://openalex.org/I2801030792 |
| authorships[12].institutions[0].ror | https://ror.org/02kx7se86 |
| authorships[12].institutions[0].type | nonprofit |
| authorships[12].institutions[0].lineage | https://openalex.org/I2801030792 |
| authorships[12].institutions[0].country_code | GB |
| authorships[12].institutions[0].display_name | Kidney Research UK |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Atsushi Imai |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Oyokyo Kidney Research Institute |
| authorships[13].author.id | https://openalex.org/A5066536967 |
| authorships[13].author.orcid | https://orcid.org/0000-0003-1061-827X |
| authorships[13].author.display_name | Takahiro Yoneyama |
| authorships[13].countries | JP |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[13].affiliations[0].raw_affiliation_string | Hirosaki University Graduate School of Medicine |
| authorships[13].institutions[0].id | https://openalex.org/I146516829 |
| authorships[13].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[13].institutions[0].country_code | JP |
| authorships[13].institutions[0].display_name | Hirosaki University |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Takahiro Yoneyama |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Hirosaki University Graduate School of Medicine |
| authorships[14].author.id | https://openalex.org/A5016000795 |
| authorships[14].author.orcid | https://orcid.org/0000-0003-0967-6835 |
| authorships[14].author.display_name | Yasuhiro Hashimoto |
| authorships[14].countries | JP |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[14].affiliations[0].raw_affiliation_string | Hirosaki University Graduate School of Medicine |
| authorships[14].institutions[0].id | https://openalex.org/I146516829 |
| authorships[14].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[14].institutions[0].type | education |
| authorships[14].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[14].institutions[0].country_code | JP |
| authorships[14].institutions[0].display_name | Hirosaki University |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Yasuhiro Hashimoto |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Hirosaki University Graduate School of Medicine |
| authorships[15].author.id | https://openalex.org/A5076273759 |
| authorships[15].author.orcid | https://orcid.org/0000-0003-1550-8379 |
| authorships[15].author.display_name | Chikara Οhyama |
| authorships[15].countries | JP |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[15].affiliations[0].raw_affiliation_string | Hirosaki University Graduate School of Medicine |
| authorships[15].institutions[0].id | https://openalex.org/I146516829 |
| authorships[15].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[15].institutions[0].type | education |
| authorships[15].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[15].institutions[0].country_code | JP |
| authorships[15].institutions[0].display_name | Hirosaki University |
| authorships[15].author_position | last |
| authorships[15].raw_author_name | Chikara Ohyama |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Hirosaki University Graduate School of Medicine |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.researchsquare.com/article/rs-711200/latest.pdf |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | The Effect of Upfront Intensive Therapy on Primary Resistance in Metastatic Castration-sensitive Prostate Cancer: A Multicenter Retrospective Study |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10543 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Prostate Cancer Treatment and Research |
| related_works | https://openalex.org/W4285594353, https://openalex.org/W4383225189, https://openalex.org/W2344063726, https://openalex.org/W2796274789, https://openalex.org/W2981596434, https://openalex.org/W1745328274, https://openalex.org/W2506739073, https://openalex.org/W2540877368, https://openalex.org/W1970512774, https://openalex.org/W2889784437 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.21203/rs.3.rs-711200/v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306402450 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Research Square (Research Square) |
| best_oa_location.source.host_organization | https://openalex.org/I4210096694 |
| best_oa_location.source.host_organization_name | Research Square (United States) |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I4210096694 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.researchsquare.com/article/rs-711200/latest.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-711200/v1 |
| primary_location.id | doi:10.21203/rs.3.rs-711200/v1 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306402450 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Research Square (Research Square) |
| primary_location.source.host_organization | https://openalex.org/I4210096694 |
| primary_location.source.host_organization_name | Research Square (United States) |
| primary_location.source.host_organization_lineage | https://openalex.org/I4210096694 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.researchsquare.com/article/rs-711200/latest.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-711200/v1 |
| publication_date | 2021-08-06 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W2801878088, https://openalex.org/W3191534679, https://openalex.org/W2952917587, https://openalex.org/W2976335348, https://openalex.org/W3024065396, https://openalex.org/W2955918565, https://openalex.org/W3102188505, https://openalex.org/W3130316650, https://openalex.org/W2938589827, https://openalex.org/W2947014957, https://openalex.org/W2947893479, https://openalex.org/W2787804990, https://openalex.org/W2777172225, https://openalex.org/W2118706228, https://openalex.org/W2975895768, https://openalex.org/W2963794755, https://openalex.org/W2983492159, https://openalex.org/W2762652685, https://openalex.org/W2988367925, https://openalex.org/W2901040765, https://openalex.org/W1578291413, https://openalex.org/W3008365787, https://openalex.org/W2899109449, https://openalex.org/W3135594221, https://openalex.org/W2167331614, https://openalex.org/W2110818436, https://openalex.org/W3124827128, https://openalex.org/W2161112598 |
| referenced_works_count | 28 |
| abstract_inverted_index.6 | 102, 153 |
| abstract_inverted_index.A | 201 |
| abstract_inverted_index.a | 38, 95 |
| abstract_inverted_index.12 | 105, 156 |
| abstract_inverted_index.In | 226 |
| abstract_inverted_index.OS | 190 |
| abstract_inverted_index.We | 1, 23, 47, 132, 145 |
| abstract_inverted_index.as | 94 |
| abstract_inverted_index.in | 12, 20, 128, 161, 171, 193, 197, 211, 242, 246 |
| abstract_inverted_index.of | 5, 29, 80, 149, 204, 218, 236 |
| abstract_inverted_index.on | 9 |
| abstract_inverted_index.or | 103, 223 |
| abstract_inverted_index.± | 60 |
| abstract_inverted_index.142 | 136 |
| abstract_inverted_index.206 | 134 |
| abstract_inverted_index.348 | 30 |
| abstract_inverted_index.ADT | 85, 121, 140, 173, 195 |
| abstract_inverted_index.May | 45 |
| abstract_inverted_index.The | 73, 89, 107, 179 |
| abstract_inverted_index.and | 44, 64, 86, 115, 122, 125, 135, 141, 154, 166, 176, 189, 239 |
| abstract_inverted_index.any | 205 |
| abstract_inverted_index.for | 138 |
| abstract_inverted_index.had | 37 |
| abstract_inverted_index.the | 3, 26, 49, 78, 84, 112, 120, 129, 139, 147, 162, 172, 194, 212, 219, 228, 234 |
| abstract_inverted_index.was | 76, 92, 158, 182, 209 |
| abstract_inverted_index.who | 36, 54 |
| abstract_inverted_index.< | 101, 104, 152, 155 |
| abstract_inverted_index.(21% | 175 |
| abstract_inverted_index.(ADT | 62 |
| abstract_inverted_index.(OS) | 118 |
| abstract_inverted_index.18%, | 167 |
| abstract_inverted_index.2008 | 43 |
| abstract_inverted_index.51%, | 177 |
| abstract_inverted_index.CRPC | 150 |
| abstract_inverted_index.high | 39 |
| abstract_inverted_index.rate | 79, 148, 203, 235 |
| abstract_inverted_index.than | 169, 191, 216 |
| abstract_inverted_index.that | 170, 192, 217 |
| abstract_inverted_index.were | 110 |
| abstract_inverted_index.with | 14, 32, 67, 185, 244 |
| abstract_inverted_index.(34%) | 222 |
| abstract_inverted_index.(9.2% | 165 |
| abstract_inverted_index.(94%) | 215 |
| abstract_inverted_index.2021. | 46 |
| abstract_inverted_index.found | 146 |
| abstract_inverted_index.grade | 206 |
| abstract_inverted_index.group | 164, 174, 196 |
| abstract_inverted_index.lower | 160 |
| abstract_inverted_index.mCSPC | 35, 245 |
| abstract_inverted_index.newly | 33 |
| abstract_inverted_index.those | 65 |
| abstract_inverted_index.(39%). | 225 |
| abstract_inverted_index.(CRPC) | 99 |
| abstract_inverted_index.cancer | 18, 98 |
| abstract_inverted_index.effect | 4 |
| abstract_inverted_index.events | 208 |
| abstract_inverted_index.group) | 63 |
| abstract_inverted_index.group. | 131 |
| abstract_inverted_index.higher | 202 |
| abstract_inverted_index.months | 157 |
| abstract_inverted_index.safety | 127 |
| abstract_inverted_index.(mCSPC) | 19 |
| abstract_inverted_index.January | 42 |
| abstract_inverted_index.adverse | 207 |
| abstract_inverted_index.between | 41, 52, 83, 119 |
| abstract_inverted_index.defined | 93 |
| abstract_inverted_index.group). | 72 |
| abstract_inverted_index.groups, | 124, 143 |
| abstract_inverted_index.groups. | 88 |
| abstract_inverted_index.medical | 27 |
| abstract_inverted_index.models. | 200 |
| abstract_inverted_index.months. | 106 |
| abstract_inverted_index.overall | 116 |
| abstract_inverted_index.primary | 10, 74, 81, 90, 237 |
| abstract_inverted_index.purpose | 75 |
| abstract_inverted_index.records | 28 |
| abstract_inverted_index.therapy | 8, 59, 181, 231 |
| abstract_inverted_index.treated | 66 |
| abstract_inverted_index.upfront | 6, 68, 87, 123, 130, 142, 163, 180, 213, 220, 229 |
| abstract_inverted_index.(upfront | 71 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.adjusted | 199 |
| abstract_inverted_index.androgen | 57 |
| abstract_inverted_index.compared | 48 |
| abstract_inverted_index.improved | 233 |
| abstract_inverted_index.observed | 210 |
| abstract_inverted_index.outcomes | 51, 241 |
| abstract_inverted_index.patients | 13, 31, 53, 137, 243 |
| abstract_inverted_index.prostate | 17, 97 |
| abstract_inverted_index.purposes | 109 |
| abstract_inverted_index.received | 55 |
| abstract_inverted_index.survival | 114, 117, 188 |
| abstract_inverted_index.CRPC-free | 113, 187 |
| abstract_inverted_index.assessing | 126 |
| abstract_inverted_index.comparing | 77, 111 |
| abstract_inverted_index.diagnosed | 34 |
| abstract_inverted_index.docetaxel | 214 |
| abstract_inverted_index.evaluated | 25 |
| abstract_inverted_index.favorable | 186 |
| abstract_inverted_index.intensive | 7, 69, 230 |
| abstract_inverted_index.practice. | 22, 248 |
| abstract_inverted_index.secondary | 108 |
| abstract_inverted_index.therapies | 70 |
| abstract_inverted_index.associated | 184 |
| abstract_inverted_index.identified | 133 |
| abstract_inverted_index.metastatic | 15 |
| abstract_inverted_index.real-world | 21, 247 |
| abstract_inverted_index.resistance | 11, 82, 91, 238 |
| abstract_inverted_index.abiraterone | 221 |
| abstract_inverted_index.conclusion, | 227 |
| abstract_inverted_index.deprivation | 58 |
| abstract_inverted_index.oncological | 50, 240 |
| abstract_inverted_index.progression | 100, 151 |
| abstract_inverted_index.bicalutamide | 61 |
| abstract_inverted_index.conventional | 56 |
| abstract_inverted_index.investigated | 2 |
| abstract_inverted_index.tumor-burden | 40 |
| abstract_inverted_index.respectively) | 168 |
| abstract_inverted_index.respectively. | 144 |
| abstract_inverted_index.significantly | 159, 183, 232 |
| abstract_inverted_index.respectively). | 178 |
| abstract_inverted_index.retrospectively | 24 |
| abstract_inverted_index.propensity-score | 198 |
| abstract_inverted_index.castration-resistant | 96 |
| abstract_inverted_index.castration-sensitive | 16 |
| abstract_inverted_index.apalutamide/enzalutamide | 224 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5109393567 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 16 |
| corresponding_institution_ids | https://openalex.org/I146516829 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.4699999988079071 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.15148458 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |